JP2024542823A5 - - Google Patents
Info
- Publication number
- JP2024542823A5 JP2024542823A5 JP2024533832A JP2024533832A JP2024542823A5 JP 2024542823 A5 JP2024542823 A5 JP 2024542823A5 JP 2024533832 A JP2024533832 A JP 2024533832A JP 2024533832 A JP2024533832 A JP 2024533832A JP 2024542823 A5 JP2024542823 A5 JP 2024542823A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286476P | 2021-12-06 | 2021-12-06 | |
| US63/286,476 | 2021-12-06 | ||
| US202263310078P | 2022-02-14 | 2022-02-14 | |
| US63/310,078 | 2022-02-14 | ||
| PCT/US2022/081031 WO2023107957A1 (en) | 2021-12-06 | 2022-12-06 | Antagonist anti-npr1 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542823A JP2024542823A (ja) | 2024-11-15 |
| JP2024542823A5 true JP2024542823A5 (cg-RX-API-DMAC7.html) | 2026-01-28 |
Family
ID=85017755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533832A Pending JP2024542823A (ja) | 2021-12-06 | 2022-12-06 | アンタゴニスト抗ｎｐｒ１抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606618B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444416A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024542823A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240112973A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022408149A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3239802A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2024001632A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024008879A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313265A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006812A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023107957A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| PT2281843T (pt) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2004011618A2 (en) | 2002-07-29 | 2004-02-05 | Hmgene, Inc. | Methods of identifying adipocyte specific genes, the genes identified, and their uses |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US20100310561A1 (en) | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| WO2010065293A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2010273585B2 (en) | 2009-07-13 | 2015-04-23 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| US9451770B2 (en) | 2012-06-08 | 2016-09-27 | Charles Despres | Method of activating immune response in plants |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| US9987330B2 (en) * | 2013-12-05 | 2018-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating or preventing pruritis by blocking natriuretic polypeptide B |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2016131943A1 (en) | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| CN112020518A (zh) * | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| EP3898700A1 (en) | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| DK3941946T3 (da) * | 2019-03-20 | 2025-03-24 | Univ California | Claudin-6-antistoffer og lægemiddelkonjugater |
| US11066469B2 (en) | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| WO2022155324A1 (en) * | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
| CN118159290A (zh) | 2021-10-11 | 2024-06-07 | 瑞泽恩制药公司 | 通过施用抗npr1抗体来影响血液动力学变化的方法 |
-
2022
- 2022-12-06 JP JP2024533832A patent/JP2024542823A/ja active Pending
- 2022-12-06 IL IL313265A patent/IL313265A/en unknown
- 2022-12-06 WO PCT/US2022/081031 patent/WO2023107957A1/en not_active Ceased
- 2022-12-06 US US18/062,450 patent/US12606618B2/en active Active
- 2022-12-06 AU AU2022408149A patent/AU2022408149A1/en active Pending
- 2022-12-06 KR KR1020247022671A patent/KR20240112973A/ko active Pending
- 2022-12-06 EP EP22847067.0A patent/EP4444416A1/en active Pending
- 2022-12-06 CA CA3239802A patent/CA3239802A1/en active Pending
- 2022-12-06 MX MX2024006812A patent/MX2024006812A/es unknown
-
2024
- 2024-05-31 CL CL2024001632A patent/CL2024001632A1/es unknown
- 2024-07-04 CO CONC2024/0008879A patent/CO2024008879A2/es unknown
-
2025
- 2025-07-17 CL CL2025002112A patent/CL2025002112A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505604A5 (cg-RX-API-DMAC7.html) | ||
| JP7559112B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| KR101160385B1 (ko) | 페길화된 Ａβ ＦＡＢ | |
| JP2024542823A5 (cg-RX-API-DMAC7.html) | ||
| US20120039882A1 (en) | Vascular Disease Therapies | |
| JP2011504872A5 (cg-RX-API-DMAC7.html) | ||
| WO2011103700A1 (zh) | 一种全人源抗her2单克隆抗体、其制备方法及用途 | |
| RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
| JP2024503784A5 (cg-RX-API-DMAC7.html) | ||
| US12606618B2 (en) | Antagonist anti-NPR1 antibodies and methods of use thereof | |
| JP2024537284A5 (cg-RX-API-DMAC7.html) | ||
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| IL294941A (en) | Inhibitors and their uses | |
| JP2024505195A5 (cg-RX-API-DMAC7.html) | ||
| JP2024526930A (ja) | 線維性疾患を緩和または治療するための薬物組成物またはキットおよびその応用 | |
| IL301713A (en) | Methods for treating dermatomyositis | |
| NZ773064B2 (en) | Anti-npr1 antibodies and uses thereof | |
| NZ773064A (en) | Anti-npr1 antibodies and uses thereof | |
| WO2022228380A1 (en) | Anti-cxcr2 antibodies and uses thereof | |
| CN120230210A (zh) | 一组sh1同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用 | |
| CN120230208A (zh) | 一组sh23同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用 | |
| CN118414354A (zh) | 拮抗剂抗npr1抗体及其使用方法 | |
| EA052748B1 (ru) | Антагонистические анти-npr1 антитела и способы их применения | |
| WO2026072993A1 (en) | Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody | |
| RU2019127917A (ru) | Антитела-миметики fgf21 и пути их применения |